Arcturus Therapeutics Holdings Inc. (ARCT) carries a Roarable Rating of E (Strong Sell) with 25/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $11.03 (-9.22% 1D, market cap $313.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ARCT ranks #924 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ARCT carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ENTA (Enanta Pharmaceuticals Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $311.9M) and PRLD (Prelude Therapeutics Incorporated) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $309.6M). Among the 5-stock peer group, CYPH leads on earnings multiple (71.3x) while CYPH leads on capital efficiency (-23.3% ROIC).
Per ARCT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001768224), Arcturus Therapeutics Holdings Inc. generated $82.0M in revenue (-46.1% YoY), -$65.8M in net income, and -$74.5M in free cash flow against $271.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 44% of 52W Range • RSI-14 at 45.3 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While ARCT currently carries a cautious 25/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.52) and Max Pain ($11.58) forces dealer call-delta covering toward $18.86.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Arcturus Therapeutics Holdings Inc. (ARCT) dropped -9.22% to $11.03, trading at 44% of its 52-week range ($5.5 – $17.96). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Arcturus Therapeutics Holdings Inc. (ARCT) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Arcturus Therapeutics Holdings Inc. (ARCT) market action, institutional positioning, and fundamental catalysts.
www.debelegger.nl report covering Arcturus Therapeutics Holdings Inc. (ARCT) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Arcturus Therapeutics Holdings Inc. (ARCT) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering Arcturus Therapeutics Holdings Inc. (ARCT) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Arcturus Therapeutics Holdings Inc. (ARCT) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Arcturus Therapeutics Holdings Inc. (ARCT) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Arcturus Therapeutics Holdings Inc. (ARCT) market action, institutional positioning, and fundamental catalysts.
Here is how Agilon Health (AGL) and Arcturus Therapeutics (ARCT) have performed compared to their sector so far this year.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -46.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ARCT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ARCT. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Arcturus Therapeutics Holdings Inc. (ARCT) ranks #924 by composite RQD confidence (25/100, grade E) and #510 by equity capitalization ($313.5M). Within this direct 5-issuer industry benchmark cohort, CYPH leads on earnings valuation at 71.3x trailing P/E, while CYPH leads on capital efficiency and profitability with -23.3% ROIC and — gross margin. CYPH currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with ARCT at 25/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ARCT
ACTIVE
Arcturus Therapeutics Holdings Inc. | E | 25/100 | — | — | -35.0% | -9.22% | $313.5M | Benchmark Subject |
| ENTA Enanta Pharmaceuticals Inc. | E | 20/100 | — | — | -35.0% | -3.95% | $311.9M | /enta-vs-arct → |
| PRLD Prelude Therapeutics Incorporated | E | 33/100 | — | — | -35.0% | -5.37% | $309.6M | /prld-vs-arct → |
| TTRX Turn Therapeutics Inc. | D- | 38/100 | — | — | -28.3% | -2.70% | $318.5M | /ttrx-vs-arct → |
| CYPH Cypherpunk Technologies Inc. | D- | 42/100 | 71.3x | — | -23.3% | -9.97% | $321.1M | /cyph-vs-arct → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Arcturus Therapeutics Holdings Inc. (ARCT) reported GAAP revenue of $82.0M (-46.1% vs. FY2024 revenue of $152.3M , and -50.8% cumulative change since FY2023) , GAAP net income of -$65.8M, operating cash flow of -$74.3M, and free cash flow of -$74.5M (-23.4% YoY). On the balance sheet, ARCT closed FY2025 with $271.1M in total assets against $0 in total debt (Altman Z-Score: 1.25, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $82.0M | -$65.8M | -$74.3M | -$74.5M | $271.1M | — |
| FY2024 (FY) | 2024-12-31 | $152.3M | -$80.9M | -$59.7M | -$60.4M | $344.1M | — |
| FY2023 (FY) | 2023-12-31 | $166.8M | -$29.7M | -$18.1M | -$18.1M | — | — |
As of 2026-11-03, Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $11.03 (-9.22% 1D, market cap $313.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ARCT ranks #924 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ARCT carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ENTA (Enanta Pharmaceuticals Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $311.9M) and PRLD (Prelude Therapeutics Incorporated) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $309.6M). Among the 5-stock peer group, CYPH leads on earnings multiple (71.3x) while CYPH leads on capital efficiency (-23.3% ROIC).
Per ARCT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001768224), Arcturus Therapeutics Holdings Inc. generated $82.0M in revenue (-46.1% YoY), -$65.8M in net income, and -$74.5M in free cash flow against $271.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ARCT last traded at $11.03 (-9.22% on volume of 1,845,038 shares), positioning the stock -18.42% below its 50-day simple moving average ($13.52) and +22.01% above its 200-day simple moving average ($9.04). Across its 52-week range of $5.50 to $17.96, ARCT sits at the 44.4% percentile with a 14-day RSI of 45.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.65 to $12.41).
Why ARCT Stock dropped -9.22% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, ARCT scores 25 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:
For a prospective investor evaluating the stock today, the pattern is a business with operating losses, negative free cash flow, and weak forensic signals, offset partly by institutional interest and a balance sheet with a Debt/Equity reading of 0.5. Any upside case would depend on the company reversing its cash-burn trajectory, which the source data does not show. The valuation tradeoff is that a $345.3M market capitalization is being applied to a business whose reported operating and net margins are both -60%. This analysis is educational and is not personalized financial advice.
Arcturus Therapeutics Holdings Inc. is a NASDAQ-listed issuer in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry, per the profile section. The profile does not describe the company's products, customers, or revenue model. Reported revenue in the SEC financials was $82.0M for FY 2025, $152.3M for FY 2024, and $166.8M for FY 2023. Not available in source data for the specific sources of revenue.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $82.0M | $-76.3M | $-65.8M | N/A | $-74.5M | $230.9M | N/A |
| FY 2024 | $152.3M | $-95.7M | $-80.9M | N/A | $-60.4M | $237.0M | N/A |
| FY 2023 | $166.8M | $-78.2M | $-29.7M | N/A | $-18.1M | N/A | N/A |
Per the SEC financials, revenue declined from $166.8M in FY 2023 to $82.0M in FY 2025, while operating losses remained in each reported year. Per the market data, gross margin is 0%, operating margin is -60%, net margin is -60%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 1.25 and the Piotroski F-Score is 2/9, with Debt/Equity of 0.5. Reported cash was $230.9M at FY 2025 year-end, compared with $237.0M at FY 2024 year-end.
Per the recent news section, the most recent item is an announcement that the company will report third-quarter financial results and provide a corporate update on November 5, 2026 (YELLOW). Other items include a TradingView estimates page, a debelegger.nl stock page, a Benzinga transcript of the Q2 2026 earnings call, a MarketBeat institutional ownership item, and a Globe and Mail item reporting a Buy from Leerink Partners (GREEN, CATALYST). The news section does not provide the content of the earnings call transcript or the Leerink rationale. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links or proprietary signals.
Risk watch items: the November 5, 2026 earnings release, which is the most immediate scheduled event, and the company's continued operating losses as shown in the financials.
Real-time company headlines, analyst actions, and sector developments for Arcturus Therapeutics Holdings Inc. (ARCT) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Arcturus Therapeutics Holdings Inc. (ARCT) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Arcturus Therapeutics Holdings Inc. (ARCT) market action, institutional positioning, and fundamental catalysts.
www.debelegger.nl report covering Arcturus Therapeutics Holdings Inc. (ARCT) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Arcturus Therapeutics Holdings Inc. (ARCT) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering Arcturus Therapeutics Holdings Inc. (ARCT) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Arcturus Therapeutics Holdings Inc. (ARCT) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Arcturus Therapeutics Holdings Inc. (ARCT) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Arcturus Therapeutics Holdings Inc. (ARCT) market action, institutional positioning, and fundamental catalysts.
Welcome to the ARCT (Arcturus Therapeutics Holdings Inc.) Roar Pit. Current RQD Composite is 25/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on ARCT, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Arcturus Therapeutics Holdings Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on ARCT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $12.15 (52-wk range $5.50 - $17.96), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).